GSK said Friday that its RSV vaccine showed “statistically significant and clinically meaningful efficacy” in adults over 60 in a 25,000-volunteer randomized trial taking place in 17 countries.
The company said that it plans to submit the data to regulators, including the Food and Drug Administration, in the second half of the year.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
